Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netupitant and palonosetron pharmacokinetic/pharmacodynamic study in pediatric chemotherapy-induced nausea and vomiting
2020-003730-20Phase 2
- Sponsor
- Helsinn
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of netupitant and palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Helsinn. Primary endpoint: PK/PD relationship between netupitant exposure and delayed-phase antiemetic efficacy.
02
Drugs
netupitantpalonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2020-003730-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003730-20.